• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Sirtris Pharmaceuticals

edit

Sirtris Pharmaceuticals (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes.

via: Sirtris

Recent Milestones

edit

• 
  Sirtris Pharmaceuticals was acquired by GlaxoSmithKline for $720M. (4/22/08)
  Posted 5/21/08 at 2:03pm via corporate-ir.net
• 
  Sirtris Pharmaceuticals received $37M in Series C funding. (4/19/06)
  Posted 5/21/08 at 2:11pm via fiercebiotech.com
• 
  Sirtris Pharmaceuticals received $27M in Series B funding. (3/8/05)
  Posted 5/21/08 at 2:09pm via bizjournals.com
• 
  Sirtris Pharmaceuticals received $13M in Series A funding. (12/1/04)
  Posted 5/21/08 at 2:09pm via bizjournals.com
• 
  Sirtris Pharmaceuticals received $5M in Seed funding. (1/1/04)
  Posted 5/21/08 at 2:09pm via sirtrispharma.com
• 
  Sirtris Pharmaceuticals added Kevin Bitterman as Co-founder.
  Posted 4/16/13 at 3:50am

Videos

Screenshots

edit

Traffic Analytics

Quantcast

Compete

Sources

1. GlaxoSmithKline to acquire Sirtris Pharmaceuticals, a world leader in 'Sirtuin' research and development (phx.corporate-ir.net) [edit]
2. HBR case article (sirtrispharma.com) [edit]
3. Sirtris closes $13 million financing (boston.bizjournals.com) [edit]
4. Sirtris Pharmaceuticals closes $27M second round (boston.bizjournals.com) [edit]
5. Sirtris pockets $37M in venture funds (fiercebiotech.com) [edit]

Share this page on Twitter or Facebook: Or copy this code to embed a widget: customize »